Cefadroxil

DRUG NAME: Cefadroxil

---

Therapeutic Class:

---

Subclass:

---

Schedule (India):

---

Route(s)

• Oral (capsules, tablets, dry syrup/oral suspension, paediatric drops)

---

Biosimilar Status:

---

Formulations Available in India

Single-ingredient formulations:

Fixed-Dose Combinations (FDCs) available in India:

---

PHARMACOKINETICS

---

Population PK Notes:

---

• Community E. coli susceptibility to first-generation cephalosporins: ~50–65% (varies regionally)
• Community K. pneumoniae susceptibility: ~40–55%
• MSSA and GAS remain highly susceptible — resistance is not a concern for Gram-positive indications

---

Key PK Comparison: Cefadroxil vs Cephalexin

1. Adherence priority → choose cefadroxil (BD — 2 doses/day is easier than 3–4)
2. Cost priority → choose cephalexin (wider generic competition, NPPA-controlled with more ceiling-price products)
3. High-dose therapy (osteomyelitis step-down) → choose cephalexin (better evidence base at 1 g q6h; cefadroxil 1 g BD is pharmacokinetically marginal for high-MIC organisms due to suboptimal fT>MIC at 12-hour intervals)
4. Availability priority (rural/remote areas) → check local availability — both are widely available but cephalexin has a slight edge in ubiquity

---

ADULT INDICATIONS + DOSING

---

• Outpatient therapy where compliance drops with each additional daily dose
• School-going children (BD = morning + evening; no midday school dose)
• Working adults (BD = before and after work; no midday workplace dose)
• 10-day courses (GAS pharyngitis) where the total ”pill burden“ over the course is substantially lower with BD dosing

---

---

Primary Indications (Approved / Standard in India)

---

PRIMARY INDICATION 1: Skin and Soft Tissue Infections (SSTI) — MSSA / Streptococcal

Includes: Cellulitis (non-purulent and purulent — when MSSA suspected/confirmed), impetigo (non-bullous and bullous), wound infections, furunculosis, carbuncle, folliculitis, erysipelas, infected eczema, post-surgical wound infection (MSSA/streptococcal), infected burns (superficial, MSSA/streptococcal), pyoderma, paronychia (acute bacterial), secondary skin infections.

Dosing Table — SSTI:

Duration of Therapy — SSTI:

• Cefadroxil 500 mg BD × 7 days = 14 capsules total (2 per day)
• Cephalexin 500 mg TDS × 7 days = 21 capsules total (3 per day)
• Cephalexin 500 mg QDS × 7 days = 28 capsules total (4 per day)
• Cloxacillin 500 mg QDS × 7 days = 28 capsules total (4 per day, empty stomach)

1. When to prefer cefadroxil over alternatives: Preferred over cephalexin when adherence to TDS/QDS dosing is a concern — school-going children, working adults, elderly on polypharmacy (fewer daily doses → less confusion). Preferred over cloxacillin/flucloxacillin for the same adherence reasons (BD food-independent dosing vs QDS empty-stomach). Preferred when the patient or caregiver specifically requests a simpler regimen. For mild-to-moderate MSSA SSTI, cefadroxil BD and cephalexin TDS are clinically equivalent — the choice is a pragmatic one.
2. When NOT to use:
3. • ⛔ Suspected or confirmed MRSA → use TMP-SMX, doxycycline, or clindamycin
   • ⛔ Bite wounds (animal or human) → anaerobic component → use amoxicillin-clavulanate
   • ⛔ Diabetic foot infection (polymicrobial) → cefadroxil monotherapy insufficient → use amoxicillin-clavulanate or piperacillin-tazobactam
   • ⛔ Necrotising fasciitis → IV broad-spectrum + surgical emergency
   • ⛔ Perianal / perineal SSTI → anaerobic component likely → add metronidazole or use amoxicillin-clavulanate
   • ⛔ Patient with history of anaphylaxis to cephalosporins or penicillins (see Part 4 for cross-reactivity guidance)
4. NLEM India status: ✔ Cefadroxil is included in NLEM India 2022.
5. Typical time to clinical response: 48–72 hours. Cellulitis erythema should stop advancing; warmth and tenderness should begin improving. Mark the erythema border with a pen to objectively track progression/regression.
6. Criteria for considering treatment failure and switching:
7. • No improvement at 72 hours → (a) reassess diagnosis (DVT, contact dermatitis, stasis dermatitis in leg cellulitis), (b) obtain wound culture, © consider MRSA → switch to TMP-SMX/doxycycline/clindamycin, (d) consider deeper infection (abscess, necrotising) → imaging + surgical consultation
   • Worsening despite 48 hours → urgent reassessment, consider IV cefazolin or broader coverage
8. Mandatory baseline investigations:
9. • RECOMMENDED: Wound swab culture and sensitivity (before starting — especially if purulent, recurrent, or treatment failure)
   • OPTIONAL: CBC, blood glucose (screen for diabetes in recurrent SSTI), renal function (if prolonged course)
10. Specialist initiation:Not required. Primary care prescribing appropriate for mild-to-moderate SSTI. Complicated or non-responding SSTI → surgical/ID referral.
11. Relevant Indian guideline source: API Textbook of Medicine (Chapter on SSTI); ICMR Antimicrobial Treatment Guidelines (2022); IDSA SSTI Guidelines (2014 — widely followed in India). ICMR and API Textbook reference first-generation cephalosporins generically for MSSA SSTI (do not specifically differentiate cefadroxil from cephalexin).
12. Key disease-specific safety warning: ⚠️ In recurrent SSTI (≥3 episodes in 12 months), screen for: (a) diabetes (HbA1c), (b) MRSA nasal carriage (decolonisation protocol), © immunodeficiency, (d) household contacts as reservoirs. Recurrent MSSA SSTI in Indian diabetic patients is extremely common — always optimise glycaemic control alongside antibiotics.
13. Dose adjustment: Renal impairment (eGFR <30) → see Part 4. Obese patients → 1 g BD. Elderly → adjust for eGFR.

---

PRIMARY INDICATION 2: Urinary Tract Infections — Acute Uncomplicated Cystitis

Dosing — Acute Uncomplicated Cystitis:

Dosing — Acute Pyelonephritis (Mild, Outpatient — Directed Therapy Only):

1. When to prefer cefadroxil: Over cephalexin when BD dosing is specifically desired for adherence (e.g., working women with busy schedules, elderly on polypharmacy). Over fluoroquinolones for uncomplicated cystitis — stewardship advantage (reserve fluoroquinolones for more serious infections). The once-daily option is a unique advantage for highly compliant patients who prefer the simplest possible regimen.
2. When NOT to use:
3. • ⛔ Complicated UTI (structural abnormality, catheter-associated, male UTI, urosepsis) → broader agents
   • ⛔ Suspected ESBL organism → nitrofurantoin (for cystitis) or carbapenem (for pyelonephritis)
   • ⛔ Enterococcal UTI → no cephalosporin has enterococcal activity → use amoxicillin/ampicillin
   • ⛔ Pseudomonas UTI → no activity
   • ⛔ Empiric pyelonephritis first-line → fluoroquinolone or parenteral agent
   • ⚠️ Indian community E. coli susceptibility to first-generation cephalosporins ~50–65% → always obtain urine culture
4. NLEM status: ✔ On NLEM 2022.
5. Time to response: Symptom improvement (frequency, dysuria) within 24–48 hours. If no improvement by 48–72 hours → check urine culture results and switch.
6. Treatment failure: Persistent symptoms at 72 hours; positive repeat culture → reassess organism susceptibility, imaging for structural cause, consider resistant organism.
7. Mandatory baseline:
8. • RECOMMENDED: Urine culture and sensitivity (midstream clean-catch) BEFORE starting — especially in India where first-generation cephalosporin resistance in E. coli is ~35–50%.
   • MANDATORY (certain groups): Pregnant women, males, recurrent UTI, treatment failure.
9. Specialist initiation: Not required for uncomplicated cystitis. Complicated UTI, pyelonephritis, recurrent UTI → urology/nephrology referral.
10. Indian guideline source: API Textbook; ICMR Treatment Guidelines (2022); AIIMS Antibiotic Policy; IDSA/ESCMID UTI Guidelines (2011/2024 update).
11. Key safety warning: ⚠️ Always obtain urine culture in India before starting empiric first-generation cephalosporin for UTI. Indian E. coli resistance to these agents is substantially higher than in Western countries. Nitrofurantoin (resistance ~10–20%) remains the best empiric option for uncomplicated cystitis per ICMR.
12. Dose adjustment: Renal impairment → Part 4 (important — many UTI patients have coexisting CKD).

---

PRIMARY INDICATION 3: Acute Pharyngitis / Tonsillitis — Group A Streptococcus (GAS)

Dosing — GAS Pharyngitis:

• Pichichero ME, Gooch WM, Rodriguez W, et al. (1994): OD cefadroxil vs TDS penicillin V × 10 days — comparable eradication rates (~90–95% for cefadroxil OD, ~85–90% for penicillin V).
• Disney FA, et al. (1992): Cefadroxil OD vs BD — equivalent outcomes.
• These studies were conducted with adequate sample sizes and are the pharmacological basis for OD cefadroxil labelling for GAS pharyngitis in many international product inserts.
• Why does OD dosing work despite the ~1.5-hour half-life? Beta-lactam bactericidal activity for GAS (which has a very low MIC — typically <0.12 mg/L for first-generation cephalosporins) requires fT>MIC for only a moderate fraction of the dosing interval. After a 1 g dose, serum levels exceed the GAS MIC for approximately 8–10 hours of the 24-hour interval — this appears sufficient for pharyngeal eradication in immunocompetent patients. Additionally, the post-antibiotic effect (PAE) of cephalosporins against streptococci extends the bactericidal window beyond the time that serum levels are measurably above MIC.

1. When to prefer cefadroxil: (a) When OD dosing is specifically desired for maximum adherence (school-going children, working adults, families with adherence challenges). (b) Non-anaphylactic penicillin allergy. © Treatment failure with amoxicillin or penicillin V (cephalosporin course for recurrence). (d) When the prescriber judges that the patient/family is unlikely to complete a BD or TDS regimen for a full 10 days. ℹ️ Amoxicillin remains the first-line agent per IAP and ICMR — cefadroxil is an excellent alternative, not the default first-line.
2. When NOT to use:
3. • ⛔ History of anaphylaxis to penicillin → avoid cephalosporins (cross-reactivity risk, though low ~1–2%) → use azithromycin 500 mg OD × 5 days
   • ⛔ Suspected peritonsillar abscess or deep neck space infection → IV antibiotics + surgical drainage
   • ⛔ Non-streptococcal pharyngitis (viral — the majority of cases) → no antibiotics
4. NLEM status: ✔ On NLEM 2022.
5. Time to response: Symptom improvement within 24–48 hours.
6. Treatment failure: Persistent symptoms at 72 hours; positive throat culture post-treatment; recurrence within 2–4 weeks.
7. Mandatory baseline:
8. • RECOMMENDED: Modified Centor / McIsaac Score. RADT for GAS if available. Throat culture (gold standard — but takes 24–48 hours).
   • In resource-limited settings: Treat based on Centor score ≥3.
9. Specialist initiation: Not required. ENT referral for recurrent pharyngitis (≥7 episodes/year) or complications.
10. Indian guideline source: IAP Guidelines on GAS pharyngitis and ARF prevention; API Textbook; ICMR AMR guidelines; ICRP (Indian Council of Rheumatic Prevention). International: AHA, IDSA pharyngitis guidelines — all widely followed in India.
11. Key disease-specific safety warning: ⚠️ Do NOT shorten below 10 days — even with OD dosing. The OD regimen is not an excuse to shorten the course — it is a simplification of the daily regimen while maintaining the full 10-day course duration. Incomplete courses risk failure of GAS eradication → ARF risk. ⚠️ Counsel emphatically: ”Take one capsule every day for 10 days — even if your throat feels completely better after day 2.“
12. Dose adjustment: Renal → Part 4.

---

PRIMARY INDICATION 4: Acute Otitis Media (AOM)

1. When to prefer cefadroxil: Only when amoxicillin, amoxicillin-clavulanate, and cefuroxime axetil are all unavailable or not tolerated. Cefadroxil’s BD dosing does not confer a significant additional advantage for AOM since amoxicillin itself supports BD dosing. Cefadroxil’s borderline H. influenzae coverage limits its usefulness — for AOM treatment failure with amoxicillin, amoxicillin-clavulanate is preferred (covers beta-lactamase-producing H. influenzae and M. catarrhalis).
2. When NOT to use: ⛔ Suspected mastoiditis or intracranial complication → IV antibiotics; ⛔ CSOM; ⛔ History of penicillin anaphylaxis.
3. NLEM status: ✔ On NLEM.
4. Time to response: 48–72 hours.
5. Treatment failure: Switch to amoxicillin-clavulanate or cefuroxime axetil.
6. Mandatory baseline: Otoscopic examination.
7. Specialist initiation: Not required for uncomplicated AOM. ENT referral for complications.
8. Indian guideline source: IAP Guidelines; API Textbook; AAP AOM Guidelines (2013).
9. Key safety warning: ⚠️ Do not confuse AOM with otitis externa — different aetiology and treatment.
10. Dose adjustment: Renal → Part 4.

---

PRIMARY INDICATION 5: Oral Step-Down from IV Cefazolin

• ✔ Afebrile ≥24–48 hours
• ✔ Clinical improvement
• ✔ Haemodynamically stable
• ✔ Tolerating oral intake
• ✔ No undrained collection
• ✔ Culture confirms susceptible organism (when available)
• ✔ Reliable patient for oral adherence

1. When to prefer cefadroxil over cephalexin for step-down: When BD dosing is specifically desired for outpatient continuation (patient being discharged home — BD dosing is simpler for home administration). For standard SSTI and UTI step-down, cefadroxil BD and cephalexin TDS are clinically equivalent.
2. When to prefer cephalexin INSTEAD of cefadroxil for step-down:
3. • Osteomyelitis / serious bone & joint infections → cephalexin 1 g q6h (4 g/day) provides better fT>MIC at high doses than cefadroxil 1 g BD (2 g/day maximum). Cefadroxil’s 2 g/day ceiling is pharmacokinetically marginal for osteomyelitis where sustained high trough levels are needed.
   • MSSA bacteraemia → cephalexin q6h (more frequent dosing) preferred by most ID specialists.
   • ⚠️ Cefadroxil should NOT be used for high-dose oral step-down in osteomyelitis — cephalexin is the more appropriate choice (higher daily dose achievable: 4 g/day vs 2 g/day).
4. NLEM status: ✔ Both cefazolin and cefadroxil on NLEM.
5. Time to response: Already responding (switch occurs AFTER response to IV).
6. Treatment failure after switch: Recurrence → reassess (inadequate absorption? undrained collection? resistance? need to return to IV?).
7. Mandatory baseline: Culture confirmation (RECOMMENDED).
8. Specialist initiation: For SSTI step-down → primary care can manage. For bacteraemia/osteomyelitis → ID specialist decision.
9. Indian guideline source: API Textbook; AIIMS Antibiotic Policy; ICMR guidelines support IV-to-oral switch.
10. Key safety warning: ⚠️ Ensure the patient will adhere to BD dosing for the full remaining duration. The advantage of BD dosing is lost if the patient skips even one daily dose (24-hour gap with no drug exposure).
11. Dose adjustment: Per renal function.

---

PRIMARY INDICATION 6: Bone and Joint Infections — MSSA (Oral Phase) — LIMITED ROLE

Why cephalexin is preferred over cefadroxil for osteomyelitis:

1. When to prefer cefadroxil: ⚠️ Rarely preferred. Use only if cephalexin is genuinely unavailable. Cephalexin 1 g q6h is the standard oral first-generation cephalosporin for osteomyelitis step-down.
2. When NOT to use: ⛔ MRSA bone/joint infection; ⛔ Polymicrobial osteomyelitis; ⛔ TB spondylitis; ⛔ Vertebral osteomyelitis (pharmacokinetically insufficient at 2 g/day).
3. NLEM status: ✔ On NLEM.
4. Time to response: CRP should decline within 1 week.
5. Treatment failure: Rising CRP → reassess → switch to cephalexin q6h (higher dose achievable) or IV therapy.
6. Mandatory baseline: Blood cultures (MANDATORY); bone biopsy culture (RECOMMENDED); CRP + ESR; MRI; renal function.
7. Specialist initiation: ⚠️ MANDATORY. Orthopaedics + ID specialist.
8. Indian guideline source: API Textbook; AIIMS Antibiotic Policy; OVIVA trial (references cephalexin/flucloxacillin, not cefadroxil specifically).
9. Key safety warning: ⚠️ Do NOT use cefadroxil for osteomyelitis if cephalexin is available. The 2 g/day ceiling is a pharmacokinetic limitation. ⚠️ Always exclude TB osteomyelitis in India.
10. Dose adjustment: Renal → Part 4.

---

Secondary Indications — Adults Only (Off-label, if any)

---

SECONDARY INDICATION 1: Dental Infections (Periapical Abscess, Dental Cellulitis)

---

SECONDARY INDICATION 2: Infective Endocarditis Prophylaxis — Dental Procedures (Penicillin-Allergic Patients)

---

SECONDARY INDICATION 3: Recurrent UTI Prophylaxis

---

SECONDARY INDICATION 4: Acne Vulgaris — Moderate (Alternative Oral Antibiotic)

---

SECONDARY INDICATION 5: Lactational Mastitis (Infective)

---

SECONDARY INDICATION 6: UTI in Pregnancy (Second-Line Agent)

---

SECONDARY INDICATION 7: Streptococcal Skin Infections — Erysipelas (Monotherapy)

---

PAEDIATRIC DOSING (Specialist Only)

---

1. Safety monitoring: Cefadroxil has an excellent safety profile in paediatric patients. No special paediatric-only monitoring is required beyond routine clinical assessment. Monitor for diarrhoea (especially in infants — risk of dehydration), allergic reactions (rash, urticaria), and oral thrush/diaper candidiasis with prolonged courses.
2. Minimum age/weight: Cefadroxil may be used from the neonatal period onwards (limited neonatal data — see below). There is no strict minimum weight threshold, but weight-based dosing (mg/kg) is mandatory for all children. Most clinical experience begins from 1 month of age.
3. Formulation suitability for children:
4. • ✔ Dry syrup/oral suspension (125 mg/5 mL, 250 mg/5 mL, 500 mg/5 mL) — widely available in India. Primary formulation for paediatric use.
   • ✔ Paediatric drops (100 mg/mL) — available from select manufacturers; useful for infants.
   • ✔ Dispersible tablets (250 mg, 500 mg) — select manufacturers; can be dispersed in water for children who cannot swallow capsules/tablets.
   • Capsules (500 mg) — suitable for older children/adolescents who can swallow capsules (generally ≥8–10 years).
5. Palatability: Cefadroxil dry syrups are generally well-accepted. Most Indian manufacturers provide flavoured suspensions (orange, mixed fruit, strawberry). Palatability is comparable to cephalexin dry syrup. ℹ️ If a child refuses one brand’s flavour, switching to another manufacturer’s product often resolves the issue.
6. Age-specific PK differences:
7. • Neonates (<28 days): Half-life prolonged to 3–6 hours due to immature renal function. Lower doses per kg or extended intervals may be needed.
   • Infants and young children (1 month – 2 years): Per-kg clearance is higher than adults — weight-based dosing in mg/kg inherently accounts for this.
   • Children >2 years: PK approximates adult values on a per-kg basis.
   • Adolescents ≥12 years or ≥40 kg: Use adult dosing.
8. Maximum dose ceiling: In all paediatric dosing, the calculated weight-based dose must NOT exceed the corresponding adult dose. Always state the adult ceiling alongside the mg/kg dose.

---

General Paediatric Dosing Framework:

---

Primary Indications — Paediatric (Approved / Standard in India)

---

PAEDIATRIC PRIMARY INDICATION 1: GAS Pharyngitis / Tonsillitis

Dosing Table — GAS Pharyngitis (Paediatric):

1. When to prefer cefadroxil: (a) OD dosing specifically desired — school-going children, families with adherence challenges, migrant/mobile families. (b) Non-anaphylactic penicillin allergy. © Treatment failure with amoxicillin (recurrence after a completed amoxicillin course). (d) Prescriber’s clinical judgement that the family is unlikely to complete a 10-day BD or TDS course. ℹ️ Amoxicillin remains the IAP/WHO first-line agent — cefadroxil is an excellent alternative, not the default.
2. When NOT to use: ⛔ History of penicillin/cephalosporin anaphylaxis → use azithromycin. ⛔ Suspected peritonsillar abscess. ⛔ Non-streptococcal pharyngitis (viral — most childhood pharyngitis is viral).
3. NLEM status: ✔ On NLEM 2022.
4. Time to response: 24–48 hours.
5. Treatment failure criteria: Persistent symptoms at 72 hours; positive throat culture post-treatment; recurrence within 2–4 weeks → consider clindamycin or amoxicillin-clavulanate for recurrence.
6. Baseline investigations: Modified Centor/McIsaac score. RADT for GAS if available. Throat culture (gold standard). In resource-limited settings: treat empirically with Centor ≥3.
7. Specialist initiation: Not required. Any paediatrician, GP, or PHC doctor can prescribe.
8. Indian guideline source: IAP Guidelines on Pharyngitis and ARF Prevention; ICRP (Indian Council of Rheumatic Prevention); API Textbook.
9. Key safety warning: ⚠️ Do NOT shorten below 10 days. The OD regimen is not a shortened course — it is a simplified daily regimen for a full 10-day course. Counsel parents emphatically: ”Give one dose every day for 10 days — even if the child feels completely well after 2 days. Stopping early can cause rheumatic fever.“
10. Dose adjustment: Renal impairment → Part 4 (rare in children with pharyngitis but relevant in CKD patients).

---

PAEDIATRIC PRIMARY INDICATION 2: Skin and Soft Tissue Infections (SSTI)

1. When to prefer cefadroxil: BD dosing advantage — eliminates school-time dose. Preferred over cloxacillin QDS (empty-stomach requirement impractical in children) and over cephalexin TDS for adherence.
2. When NOT to use: ⛔ MRSA suspected (screen for CA-MRSA in recurrent SSTI). ⛔ Bite wounds → amoxicillin-clavulanate. ⛔ Neonatal skin infections (specialist management — often IV agents needed).
3. NLEM status: ✔ On NLEM.
4. Time to response: 48–72 hours. Mark cellulitis margins.
5. Treatment failure: No improvement at 72 hours → wound culture, consider MRSA, broader agent.
6. Baseline: Wound swab C/S (recommended). Blood glucose screening if recurrent SSTI in obese child.
7. Specialist initiation: Not required for mild-moderate SSTI.
8. Indian guideline source: IAP Guidelines; API Textbook.
9. Key safety warning: ⚠️ In recurrent paediatric SSTI in India, always consider: (a) underlying diabetes/prediabetes (increasingly common), (b) CA-MRSA (increasing in Indian metros), © nutritional deficiency/immunodeficiency, (d) hygiene/overcrowding factors.
10. Dose adjustment: Renal impairment → Part 4 (uncommon in children).

---

PAEDIATRIC PRIMARY INDICATION 3: Urinary Tract Infections (UTI)

1. When to prefer cefadroxil: BD dosing advantage over cephalexin TDS for outpatient completion. Useful when urine culture confirms susceptible E. coli/K. pneumoniae/P. mirabilis.
2. When NOT to use: ⛔ Febrile UTI in infant <3 months → IV. ⛔ Toxic-appearing child → IV. ⛔ Suspected ESBL organism → nitrofurantoin (cystitis) or carbapenem (pyelonephritis). ⛔ Enterococcal UTI → amoxicillin/ampicillin.
3. NLEM status: ✔ On NLEM.
4. Time to response: Symptom improvement within 48 hours.
5. Treatment failure: Persistent fever at 48–72 hours → reassess, imaging (USG KUB — mandatory for first febrile UTI in children), switch antibiotics per C/S.
6. Baseline: ⚠️ MANDATORY: Urine culture and sensitivity BEFORE starting antibiotics. USG KUB recommended for all first febrile UTI in children. MCU/DMSA scan per paediatric nephrology protocol.
7. Specialist initiation: Uncomplicated cystitis → GP/paediatrician. Pyelonephritis or recurrent UTI → paediatric nephrologist.
8. Indian guideline source: IAP Guidelines on UTI in Children; API Textbook; Indian Paediatric Nephrology Group (IPNG) guidelines.
9. Key safety warning: ⚠️ All first-episode febrile UTI in children <2 years requires imaging workup (USG KUB at minimum) to rule out structural abnormality (VUR, PUJ obstruction). Do not simply treat and discharge.
10. Dose adjustment: Renal impairment → Part 4.

---

PAEDIATRIC PRIMARY INDICATION 4: Acute Otitis Media (AOM)

1. When to prefer cefadroxil: Only when amoxicillin is not tolerated (non-anaphylactic allergy, GI intolerance). BD dosing provides modest advantage over cephalexin TDS.
2. When NOT to use: ⛔ First-line (amoxicillin is superior for AOM). ⛔ Suspected mastoiditis or intracranial complication → IV antibiotics + urgent ENT referral.
3. NLEM status: ✔ On NLEM.
4. Time to response: 48–72 hours.
5. Treatment failure: No improvement at 72 hours → switch to amoxicillin-clavulanate or cefuroxime axetil.
6. Baseline: Otoscopic/pneumatic otoscopy examination. Tympanometry if available.
7. Specialist initiation: Not required. ENT referral for complications or recurrent AOM (≥3 episodes in 6 months or ≥4 in 12 months).
8. Indian guideline source: IAP Guidelines; AAP AOM Guidelines (2013).
9. Key safety warning: ⚠️ Observation without antibiotics is appropriate for mild AOM in children ≥2 years (watch-and-wait 48–72 hours) per AAP guidelines — applicable in Indian practice if reliable follow-up is possible.
10. Dose adjustment: Renal → Part 4.

---

PAEDIATRIC PRIMARY INDICATION 5: Oral Step-Down from IV Cefazolin

---

Secondary Indications — Paediatric (Off-label, if any)

---

PAEDIATRIC SECONDARY INDICATION 1: Infective Endocarditis Prophylaxis — Dental Procedures

---

PAEDIATRIC SECONDARY INDICATION 2: Recurrent UTI Prophylaxis

---

Neonatal Dosing:

---

MISSED DOSE / DELAYED DOSE GUIDANCE

---

For twice-daily (BD — q12h) dosing:

• If a dose is remembered within 6 hours of the scheduled time → take the missed dose immediately. Then take the next dose at the regular time.
• If more than 6 hours have passed → skip the missed dose. Take the next dose at the regular scheduled time.
• ⛔ Never double up — do not take two doses at once to make up for a missed dose.

For once-daily (OD — q24h) dosing (GAS pharyngitis):

• If a dose is remembered within 12 hours of the scheduled time → take the missed dose immediately. Then take the next dose at the regular time the following day.
• If more than 12 hours have passed → skip the missed dose. Take the next dose at the regular scheduled time the next day.
• ⛔ Never double up.

• Cefadroxil does NOT have rebound effects upon discontinuation or resumption.
• If multiple consecutive doses are missed (≥2–3 days of the course), the antibiotic course becomes ineffective. The infection may not be adequately treated.
• • For SSTI/UTI: Restart the course from the beginning if significant doses were missed and infection has not resolved.
  • For GAS pharyngitis: If ≥3 consecutive doses are missed during the 10-day course, restart the full 10-day course from day 1 — incomplete GAS eradication risks ARF.
• No re-titration needed — cefadroxil can be resumed at the full dose immediately.
• No withdrawal syndrome or immunogenicity concerns.

---

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

---

---

Reconstitution — Dry Syrup / Oral Suspension (Powder for Reconstitution):

• Shake the bottle well before each dose (drug settles on standing).
• Use the measuring cup, dosing syringe, or calibrated spoon provided with the product. ⛔ Do NOT use household teaspoons/tablespoons — they are inaccurate and cause dosing errors.
• Administer directly into the child’s mouth using the dosing syringe for infants (reduces spillage).
• May be mixed with a small amount of milk, juice, or water immediately before administration if the child resists the taste — but give the full mixed volume to ensure the entire dose is received.

Oral Administration Notes — Capsules and Tablets:

---

RENAL ADJUSTMENT

---

Adult Renal Dosing Adjustment:

Paediatric Renal Dosing Adjustment:

---

HEPATIC ADJUSTMENT

---

---

CONTRAINDICATIONS

---

• Includes: anaphylaxis (type I hypersensitivity — urticaria, angioedema, bronchospasm, hypotension, cardiovascular collapse), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug reaction with eosinophilia and systemic symptoms (DRESS) attributed to any cephalosporin.
• Cephalosporin cross-reactivity within the class: Cross-reactivity between cephalosporins is side-chain dependent, not uniform across the class. However, if a patient had anaphylaxis to ANY cephalosporin, avoid ALL cephalosporins unless the specific side-chain relationship is known and the non-cross-reactive cephalosporin has been confirmed safe by an allergist.
• Clinical rationale: Re-exposure after anaphylaxis risks fatal anaphylaxis.

• Cross-reactivity between penicillins and cephalosporins: Historically estimated at ~10% (older literature, confounded by impurities). Current evidence: true cross-reactivity rate is ~1–2% for cephalosporins overall, and is primarily R1 side-chain-dependent, not beta-lactam ring-dependent.
• Cefadroxil-specific cross-reactivity: Cefadroxil’s side chain (para-hydroxyphenylglycine) is structurally similar to the side chains of amoxicillin and ampicillin (both contain phenylglycine or hydroxyphenylglycine moieties). Therefore, the cross-reactivity risk between amoxicillin/ampicillin and cefadroxil may be HIGHER than average (~1–2% overall) — potentially ~5–10% based on shared R1 side-chain structure. This is the same concern as for cephalexin (which also has a phenylglycine side chain).
• Clinical guidance:
• • ⛔ If the patient had confirmed anaphylaxis to amoxicillin or ampicillin specifically → avoid cefadroxil (shared side chain → higher cross-reactivity risk). Use a structurally dissimilar cephalosporin (e.g., cefuroxime — different R1 side chain) under allergist supervision, or use a non-beta-lactam alternative.
  • ⚠️ If the patient had anaphylaxis to a non-aminopenicillin (e.g., penicillin V, penicillin G, flucloxacillin) → cefadroxil may be used with caution (different side chains → lower cross-reactivity risk, estimated ~1%). Administer the first dose under observation (30–60 minutes) in a facility with anaphylaxis management capability.
  • If the patient had non-severe penicillin allergy (maculopapular rash, GI upset) → cefadroxil can generally be used. Observe for 30 minutes after first dose.

• Re-exposure to any cephalosporin after these severe cutaneous adverse reactions is absolutely contraindicated. These reactions are not necessarily side-chain-specific and may represent broader beta-lactam hypersensitivity.

---

CAUTIONS

---

⚠️ High-priority cautions:

• Cefadroxil accumulates in renal impairment → increased risk of adverse effects (GI intolerance, neurotoxicity at extreme levels).
• Monitoring required: Estimate CrCl/eGFR before starting. Dose adjustment mandatory — see Renal Adjustment table above.
• Special concern in elderly patients: ”Normal“ serum creatinine may mask CrCl <50 mL/min in elderly patients with low muscle mass. Always calculate CrCl using Cockcroft-Gault.

• All cephalosporins carry a risk of CDI, though first-generation cephalosporins are considered lower risk than third-generation cephalosporins and fluoroquinolones.
• Monitoring required: Monitor for diarrhoea during and up to 8 weeks after completing therapy. If ≥3 loose stools/day develop during or after cefadroxil therapy, consider CDI. Send stool for C. difficile toxin assay. Discontinue cefadroxil if CDI is confirmed. Do NOT use anti-motility agents (loperamide) in suspected CDI.
• Patients with prior CDI episodes are at higher risk of recurrence with any antibiotic exposure.

• Cephalosporin-induced neurotoxicity (including seizures) is a recognised class effect, primarily with parenteral cephalosporins at high doses and in renal impairment. It is rare with oral cefadroxil at standard doses. However, in patients with pre-existing seizure disorder AND renal impairment, cefadroxil accumulation could theoretically lower the seizure threshold.
• Monitoring required: Use with caution in patients with both seizure disorder and significant renal impairment (CrCl <25 mL/min). Adjust dose per renal table.

• Cross-reactivity risk is low (~1–2% overall; slightly higher for amoxicillin/ampicillin-specific allergy due to shared side chain — see Contraindications).
• Action required: Cefadroxil may be used. Observe the patient for 30 minutes after the first dose in a facility with anaphylaxis management capability. Counsel the patient about signs of allergic reaction (rash, swelling, difficulty breathing).

---

Standard cautions:

• Risk of superinfection: Oral/vaginal candidiasis (thrush, vaginal yeast infection), antibiotic-associated diarrhoea (non-CDI).
• Monitor for oral thrush (white patches in mouth), vaginal symptoms (itching, discharge), persistent diarrhoea.
• Consider prophylactic oral nystatin or fluconazole for patients on prolonged courses (>2 weeks) who are immunocompromised or have a history of recurrent candidiasis.

• Cefadroxil dry syrup contains sucrose (most Indian formulations). The quantity of sucrose per dose is small and unlikely to significantly affect blood glucose in most diabetic patients, but should be noted for patients on strict carbohydrate-controlled diets or brittle diabetes.
• ℹ️ Capsules and tablets are sucrose-free.
• Cephalosporins can cause false-positive urine glucose with copper-reduction methods (Benedict’s test, Clinitest). Use glucose oxidase-based methods (Diastix, glucometer) for urine glucose testing in patients on cefadroxil. This is a class effect of cephalosporins.

• Cephalosporins can cause a positive direct antiglobulin test (DAT / direct Coombs’ test) without haemolytic anaemia. This is a class effect. Clinically significant haemolytic anaemia is extremely rare.
• Relevant in: neonates (Coombs’ testing for HDN), pre-transfusion testing, autoimmune haemolytic anaemia workup.
• Inform the blood bank/haematology team if the patient is on cefadroxil and requires cross-matching or Coombs’ testing.

• Any antibiotic use can disrupt the gut microbiome and potentially trigger IBD flares. Use cefadroxil in IBD patients only when clearly indicated. Monitor for increased stool frequency or bloody stools.

• Probenecid blocks renal tubular secretion of cefadroxil via OAT1/OAT3 → increased serum levels and prolonged half-life. This is an intentional drug interaction in the (rarely used) cefadroxil + probenecid FDC. If probenecid is co-prescribed for gout, monitor for cefadroxil-related adverse effects.

• Aminoglycosides (gentamicin, amikacin), vancomycin, amphotericin B, NSAIDs (chronic use), contrast media — when co-administered with cefadroxil, may increase the risk of nephrotoxicity and subsequent cefadroxil accumulation. Monitor renal function more frequently.

---

PREGNANCY

---

Common indications in pregnancy:

Preferred alternatives in Indian obstetric practice (for indications where cefadroxil might be considered):

• Maternal: Standard clinical monitoring. No cefadroxil-specific maternal monitoring required beyond routine antenatal care. Monitor for clinical response (UTI symptoms, pharyngitis, SSTI).
• Fetal: No cefadroxil-specific fetal monitoring required. Standard antenatal ultrasound schedule is sufficient.
• Neonate (post-delivery, if cefadroxil was used peripartum): No specific neonatal observation for cefadroxil exposure. No neonatal withdrawal, respiratory depression, or jaundice attributed to cefadroxil.

---

LACTATION

---

• ✔ Diarrhoea (mild, self-limited — most common potential effect; due to small amounts of drug altering infant gut flora)
• ✔ Oral thrush / diaper candidiasis (due to disruption of normal flora)
• ✔ Allergic reactions (rash, urticaria — very rare; consider if the infant has a known beta-lactam allergy)
• ✔ Feeding difficulties (irritability, refusal to feed — very rare)

• Cephalexin — identical lactation safety profile, same low RID
• Amoxicillin — compatible with breastfeeding
• Penicillin V — compatible with breastfeeding

---

ELDERLY

---

Risks specific to elderly:

Monitoring frequency adjustments in elderly:

---

MAJOR DRUG INTERACTIONS

---

• No CYP450 metabolism → no CYP-mediated interactions
• Low protein binding (~20%) → no protein displacement interactions
• No significant P-gp, OATP, BCRP, OCT2, or MATE involvement at therapeutic concentrations
• Renal elimination via glomerular filtration + tubular secretion (OAT1/OAT3)

Food-Drug Interactions:

Herb-Drug Interactions (India-specific):

---

MODERATE DRUG INTERACTIONS

---

Laboratory Test Interactions (Drug-Lab interactions):

---

COMMON ADVERSE EFFECTS

---

Very Common (≥10%):

Common (1–10%):

---

SERIOUS ADVERSE EFFECTS

---

---

MONITORING REQUIREMENTS

---

---

Baseline (Before Starting):

---

After Initiation / During Treatment:

---

Long-Term / Maintenance Monitoring (For Prolonged Courses >14 Days or Prophylactic Use):

---

---

• For short courses (5–10 days): No ongoing monitoring needed after course completion unless adverse effects developed.
• For prophylactic use (recurrent UTI): Monitor as above until prophylaxis is discontinued (specialist decision).
• Post-treatment: No long-term monitoring required after completing a cefadroxil course.

---

PATIENT COUNSELLING

---

---

---

• ”Take this medicine twice a day — once in the morning and once in the evening — about 12 hours apart. For example, 8 AM and 8 PM.“
• ”For throat infection (strep throat), your doctor may prescribe it once a day — take it at the same time every day.“
• ”You can take it with food or without food — whichever you prefer. Taking it with a meal may reduce stomach upset.“
• ”Swallow capsules and tablets whole with a full glass of water. Do NOT crush, chew, or open capsules.“
• ”For liquid medicine (syrup/suspension): Shake the bottle well before every dose. Use the measuring cup or syringe provided — do NOT use a household spoon, as it may give the wrong amount.“
• ”After mixing the powder to make the liquid medicine, store it in the fridge and use it within 14 days. Write the date you mixed it on the bottle. Throw away any leftover medicine after 14 days.“

---

• ”If you take it twice a day and forget a dose: Take it as soon as you remember, but only if there are more than 6 hours until your next dose. If less than 6 hours remain, skip the missed dose and take the next one at the regular time.“
• ”If you take it once a day (for throat infection) and forget: Take it as soon as you remember, but only if there are more than 12 hours until your next dose. If less than 12 hours remain, skip the missed dose and take the next one tomorrow at the regular time.“
• ”Never take two doses at once to make up for a missed dose.“
• ”If you miss a day during a throat infection course, add one extra day at the end to make up the full 10 days.“

---

• ”You may experience mild loose stools or diarrhoea — this is the most common side effect. It happens because the medicine affects some of the normal healthy bacteria in your gut. It usually settles on its own. Drink plenty of fluids.“
• ”You may feel mild nausea or stomach discomfort — taking the medicine with food usually helps.“
• ”Women may develop vaginal itching or a white discharge (yeast infection) during or after the course. This is treatable — inform your doctor.“
• ”Babies and young children may develop white patches in the mouth (oral thrush) or a diaper rash. Inform your doctor.“

---

• ”⚠️ Severe diarrhoea (more than 5–6 loose stools a day), especially if it is watery, bloody, or has mucus — this could be a serious bowel infection caused by the antibiotic.“
• ”⚠️ Skin rash, hives (raised itchy bumps), swelling of the face/lips/tongue, or difficulty breathing — this could be a serious allergic reaction. Go to the nearest hospital immediately.“
• ”⚠️ Yellow eyes or skin, very dark urine, severe abdominal pain — these could be signs of a rare liver or blood problem.“
• ”⚠️ Fever, severe sore throat, or mouth ulcers developing during the antibiotic course — these could rarely be a sign of a blood cell problem.“
• ”⚠️ If your infection is not improving after 3 days of taking the medicine — contact your doctor. The medicine may need to be changed.“

---

• ”There is no strict food restriction with this medicine. You can eat normally. You can drink milk and dairy products.“
• ”Alcohol: It is best to avoid alcohol while you are fighting an infection. This medicine does not cause a dangerous reaction with alcohol (unlike some other antibiotics), but alcohol can slow your recovery.“
• ”This medicine does NOT cause drowsiness — you can drive and operate machinery normally.“
• ”Do NOT take any other antibiotic at the same time without your doctor’s advice.“

---

• ”Store capsules and tablets in a cool, dry place — below 30°C. Keep them in the original packaging. Protect from moisture.“
• ”In hot weather (Indian summer), avoid storing medicines near windows, in cars, or in direct sunlight. A cupboard away from the kitchen stove is ideal.“
• ”Liquid medicine (after mixing): Keep in the refrigerator (2–8°C). Use within 14 days. If you do not have a refrigerator, keep it in the coolest part of the house and use within 7 days.“
• ”Keep all medicines out of reach of children.“

---

• ”Take this medicine for the full number of days prescribed by your doctor — even if you feel completely better before the course is finished.“
• ”For throat infection (strep throat): You MUST complete all 10 days. Stopping early — even if your throat feels better after 2 days — can allow the bacteria to survive and cause a serious heart disease called rheumatic fever. This is especially important in India.“
• ”For skin infection: Complete the full 5–7 days (or as prescribed).“
• ”For urine infection: Complete the full 5–7 days (or as prescribed). Symptoms may improve within 1–2 days, but the bacteria may not be fully cleared.“
• ”Do NOT stop early. Do NOT save leftover antibiotics for later use. Do NOT share your antibiotics with anyone else.“

---

• ”Return to your doctor if symptoms are not improving after 3 days.“
• ”Return immediately if symptoms are getting worse at any point.“
• ”For throat infection: No routine follow-up throat culture is needed if symptoms resolve. Return if symptoms recur within 2–4 weeks.“
• ”For urine infection: Your doctor may request a repeat urine test after completing the course to confirm the infection is cleared — this is especially important in pregnant women, children, and patients with recurrent UTIs.“

---

---

• Dose preparation: ”Shake the bottle well. Use the measuring device provided. DO NOT use a household spoon.“
• Timing: ”Give doses at the same times every day. Set a phone alarm as a reminder.“
• Storage: ”Keep the liquid medicine in the fridge. Mark the date you mixed it. Throw it away after 14 days.“
• Monitoring: ”Watch for diarrhoea (especially in babies — it can cause dehydration quickly), rash, vomiting, or refusal to eat/drink.“
• When to return: ”Bring the child back if: (a) fever is not coming down after 2–3 days, (b) the child is vomiting every dose and cannot keep the medicine down, © the child develops a rash, (d) diarrhoea becomes severe or bloody, (e) the child seems more unwell than before.“
• Course completion: ”Complete ALL 10 days for throat infection. Do NOT stop early even if the child seems well.“
• For elderly patients on polypharmacy: ”If the patient is taking many medicines, use a pill box or daily medicine tray. Cefadroxil is only twice a day — label the box clearly (MORNING + EVENING).“

---

---

BRANDS AVAILABLE IN INDIA

---

---

---

PRICE RANGE (INR)

---

---

---

---

---

---

CLINICAL PEARLS

---

---

---

---

---

---

---

VERSION

---

REFERENCES

1. CDSCO Product Inserts — Cefadroxil monohydrate capsules 500 mg and dry syrup 250 mg/5 mL: Droxyl (Cipla Ltd); Odoxil (Sun Pharmaceutical Industries Ltd); Cefadur (Aristo Pharmaceuticals). Reviewed for: approved indications, dosing, contraindications, adverse effects, drug interactions, pharmacokinetic data. Insert revision dates: 2021–2023 (as available on CDSCO and manufacturer websites).
2. National List of Essential Medicines (NLEM) India, 2022 — Ministry of Health and Family Welfare, Government of India. Cefadroxil listed under Section 6 (Anti-infective medicines), Sub-section 6.2 (Antibacterials), Category: First-generation cephalosporins (oral).
3. National Pharmaceutical Pricing Authority (NPPA) — Drug Prices Control Order (DPCO) ceiling price notifications for cefadroxil formulations. Accessed via nppa.gov.in, 2024–2025.
4. Indian Pharmacopoeia (IP) 2022 — Indian Pharmacopoeia Commission, Ghaziabad. Monograph on Cefadroxil and Cefadroxil Monohydrate — physicochemical specifications, identification, assay methods.
5. Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) — Jan Aushadhi product catalogue. Accessed via janaushadhi.gov.in, 2025. Cefadroxil capsules 500 mg listed.

---

1. API Textbook of Medicine — Association of Physicians of India. 11th Edition, 2019. Chapters on: Antimicrobial Therapy (rational antibiotic prescribing, first-generation cephalosporin use); Skin and Soft Tissue Infections; Urinary Tract Infections; Upper Respiratory Tract Infections; Infective Endocarditis.
2. ICMR Treatment Guidelines on Antimicrobial Use in Common Syndromes, 2022 — Indian Council of Medical Research. Sections on: Empiric antibiotic therapy for community-acquired SSTI, UTI, upper respiratory infections. First-generation cephalosporins referenced for MSSA SSTI and culture-directed UTI therapy.
3. ICMR Annual Report on Antimicrobial Resistance (AMR) Surveillance, 2023 — Indian Council of Medical Research, National AMR Surveillance Network. Community E. coli and K. pneumoniae susceptibility data for first-generation cephalosporins in India.
4. IAP (Indian Academy of Pediatrics) Guidelines — Guidelines on Management of Acute Pharyngitis and Prevention of Rheumatic Fever (updated 2017); Guidelines on Urinary Tract Infections in Children (2011/2017 update); Guidelines on Acute Otitis Media. IAP Drug Formulary.
5. AIIMS Antibiotic Policy — All India Institute of Medical Sciences, New Delhi. Hospital antibiotic policy manual (current edition). Sections on first-generation cephalosporin use, IV-to-oral switch protocols, SSTI and UTI management.
6. FOGSI Guidelines — Federation of Obstetric and Gynaecological Societies of India. Guidelines on UTI in Pregnancy; Safe Drug Use in Pregnancy and Lactation.
7. ICRP (Indian Council of Rheumatic Prevention) — Guidelines on primary and secondary prevention of acute rheumatic fever and rheumatic heart disease.

---

1. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition (2023) — Brunton LL, Knollmann BC (eds). Chapter on Cephalosporins (Chapter 58 / Beta-Lactam Antibiotics). Used for: detailed pharmacology, pharmacokinetics (bioavailability, Vd, protein binding, half-life, excretion, metabolism, transporter data), mechanism of action, spectrum of activity, PK/PD principles (fT>MIC), cross-reactivity between beta-lactams.
2. Harrison’s Principles of Internal Medicine, 21st Edition (2022) — Loscalzo J, Fauci AS, Kasper DL, et al (eds). Chapters on: Infectious Disease (Cellulitis, Pharyngitis, UTI, Osteomyelitis); Antimicrobial Agents (Cephalosporins). Used for: clinical context of cefadroxil indications, treatment durations, disease management principles.

---

1. Pichichero ME, Gooch WM, Rodriguez W, et al. ”Effective short-course treatment of acute group A beta-hemolytic streptococcal tonsillopharyngitis: Ten days of penicillin V vs. 5 days or 10 days of cefadroxil.“ Arch Pediatr Adolesc Med, 1994; 148(10):1053-1060. — Evidence basis for cefadroxil OD dosing for GAS pharyngitis.
2. Disney FA, Dillon H, Blumer JL, et al. ”Cephalosporin treatment of pharyngitis and tonsillitis: a comparison of cefadroxil once daily vs. twice daily.“ Clin Pediatr (Phila), 1992; 31(3):159-167. — Evidence basis for OD vs BD cefadroxil dosing equivalence for GAS pharyngitis.
3. OVIVA Trial — Li HK, Rombach I, Zamber R, et al. ”Oral versus intravenous antibiotics for bone and joint infection.“ N Engl J Med, 2019; 380(5):425-436. — Context for oral step-down in osteomyelitis (references cephalexin/flucloxacillin, not cefadroxil specifically — used to support the recommendation that cephalexin, not cefadroxil, is preferred for osteomyelitis step-down).
4. DANCE Trial — Cranendonk DR, Lavrijsen APM, Prins JM, et al. ”Cellulitis treatment duration: a randomized clinical trial.“ N Engl J Med, 2024. — Evidence for short-course cellulitis treatment (5 vs 12 days). Referenced for SSTI duration guidance.

---

1. LactMed (Drugs and Lactation Database) — National Library of Medicine (NIH). Monograph on Cefadroxil. Accessed 2025. Used for: breast milk excretion data, relative infant dose (RID), compatibility assessment.

---

1. Aronoff GR, Bennett WM, Berns JS, et al.Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th Edition. American College of Physicians, 2007. Cefadroxil renal dosing table.

---

1. IDSA Practice Guidelines for Acute Bacterial Rhinosinusitis, Pharyngitis, SSTI, and UTI — Various authors, published in Clinical Infectious Diseases, 2011–2014. Referenced for: treatment duration, empiric therapy guidance, treatment failure criteria.
2. AHA Guidelines for Prevention of Infective Endocarditis — Wilson W, Taubert KA, Gewitz M, et al. Circulation, 2007; 116(15):1736-1754. Updated 2021. Referenced for: IE prophylaxis dosing, indications for prophylaxis, drug selection.
3. AAP Clinical Practice Guideline: Diagnosis and Management of Acute Otitis Media — Lieberthal AS, Carroll AE, Chonmaitree T, et al. Pediatrics, 2013; 131(3):e964-e999. Referenced for: AOM management algorithm, antibiotic selection, observation option.
4. WHO Model Prescribing Information: Drugs Used in Bacterial Infections — World Health Organization. Referenced for: cefadroxil pregnancy safety, general dosing guidance.

---